JP2009529540A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529540A5
JP2009529540A5 JP2008558543A JP2008558543A JP2009529540A5 JP 2009529540 A5 JP2009529540 A5 JP 2009529540A5 JP 2008558543 A JP2008558543 A JP 2008558543A JP 2008558543 A JP2008558543 A JP 2008558543A JP 2009529540 A5 JP2009529540 A5 JP 2009529540A5
Authority
JP
Japan
Prior art keywords
tetrazole
conr
alkyl
conh
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008558543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529540A (ja
JP4851546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063631 external-priority patent/WO2007106721A2/en
Publication of JP2009529540A publication Critical patent/JP2009529540A/ja
Publication of JP2009529540A5 publication Critical patent/JP2009529540A5/ja
Application granted granted Critical
Publication of JP4851546B2 publication Critical patent/JP4851546B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008558543A 2006-03-10 2007-03-09 肥満治療に有用なカンナビノイド受容体アンタゴニスト／インバースアゴニスト Expired - Fee Related JP4851546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78148506P 2006-03-10 2006-03-10
US60/781,485 2006-03-10
PCT/US2007/063631 WO2007106721A2 (en) 2006-03-10 2007-03-09 Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

Publications (3)

Publication Number Publication Date
JP2009529540A JP2009529540A (ja) 2009-08-20
JP2009529540A5 true JP2009529540A5 (enExample) 2010-07-15
JP4851546B2 JP4851546B2 (ja) 2012-01-11

Family

ID=38510173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558543A Expired - Fee Related JP4851546B2 (ja) 2006-03-10 2007-03-09 肥満治療に有用なカンナビノイド受容体アンタゴニスト／インバースアゴニスト

Country Status (8)

Country Link
US (2) US7687481B2 (enExample)
EP (1) EP1993560B1 (enExample)
JP (1) JP4851546B2 (enExample)
CN (1) CN101437398A (enExample)
AT (1) ATE538650T1 (enExample)
AU (1) AU2007226673A1 (enExample)
CA (1) CA2647031A1 (enExample)
WO (1) WO2007106721A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007112688A (ru) * 2004-09-06 2008-10-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia
JP2009541283A (ja) * 2006-06-20 2009-11-26 アストラゼネカ アクチボラグ 治療薬
GB0622569D0 (en) * 2006-11-11 2006-12-20 7Tm Pharma As Cannabinoid receptor modulators
CA2673359A1 (en) * 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
US7655685B2 (en) * 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
RU2392943C2 (ru) * 2007-11-22 2010-06-27 Людмила Александровна Орлова Способ разгрузочно-диетической терапии
WO2009074782A1 (en) 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
KR20100098563A (ko) * 2007-12-18 2010-09-07 사노피-아벤티스 아제티딘 유도체, 그의 제법 및 치료에서의 그의 적용
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN104262267B9 (zh) * 2008-03-18 2019-04-12 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
ES2349838B1 (es) * 2009-05-04 2011-11-15 Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanitaria (Fundacion Im Derivados de pirazol bivalentes como inhibidores de ingesta
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
CN102260246B (zh) * 2010-05-28 2014-08-13 范如霖 低毒性cb1受体抑制剂、其制备方法及其在制备戒毒、减肥或治疗糖尿病药物中的应用
JP5986098B2 (ja) * 2010-11-24 2016-09-06 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション インテグリン結合キナーゼ阻害剤
CN102603713B (zh) * 2011-01-25 2014-05-14 范如霖 手性cb1受体抑制剂、制备方法及其医学用途
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102212058B (zh) * 2011-04-14 2014-04-02 范如霖 “单一的复合药”：手性含氮杂环酯、合成法及其在制备低毒性cb1受体抑制剂中的应用
CN103554025B (zh) * 2011-05-12 2016-08-10 范如霖 3-砒唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
CN102250006B (zh) * 2011-05-12 2014-03-05 范如霖 3-吡唑羧酸酰胺类化合物、其制备方法及其在制备作为cb1受体抑制剂药物中的应用
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
PT2736888E (pt) * 2011-07-26 2016-02-17 Sanofi Sa Derivados do ácido 3-heteroaroilamino-propiónico e o seu uso como produtos farmacêuticos
CA2818944C (en) * 2011-09-30 2016-05-10 National Health Research Institutes Pyrazole compounds
BR102012017421A2 (pt) 2012-07-13 2015-04-14 Proteimax Biotecnolgia Ltda Peptídeo, composicão farmacêutica, ligante de receptor cb, metodo para modular a funcao de receptor cb, uso, método para o tratamento de obesidade, e, método para promover a redução de peso estetica em um indivíduo
EP3152200A1 (en) 2014-06-06 2017-04-12 Research Triangle Institute Apelin receptor (apj) agonists and uses thereof
US10100059B2 (en) 2015-12-09 2018-10-16 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP3526209B1 (en) * 2016-10-12 2025-04-16 Research Triangle Institute Heterocyclic apelin receptor (apj) agonists and uses thereof
WO2018068120A1 (pt) * 2016-10-13 2018-04-19 Proteimax Biotecnologia Ltda Uso de composto, intermediário de síntese, composição farmacêutica e método terapêutico neuromodulador
KR101974414B1 (ko) * 2017-09-12 2019-05-02 주식회사 티에스디라이프사이언스 1h-피라졸-3-아마이드계 화합물 유도체를 포함하는 섬유증 예방 또는 치료용 조성물
CA3090764A1 (en) * 2018-01-30 2019-08-08 Pi Industries Ltd Novel anthranilamides, their use as insecticide and processes for preparing the same
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
IL317596A (en) * 2019-01-15 2025-02-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Peripheral CB1 receptor inhibitors
WO2022164239A1 (ko) * 2021-01-28 2022-08-04 주식회사 파미노젠 피라졸-카르복스아미드 유도체 화합물 및 이의 용도
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease
WO2025199092A1 (en) * 2024-03-20 2025-09-25 The Trustees Of Indiana University Ship1 modulators and methods of treatment and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
FR2856683A1 (fr) 2003-06-25 2004-12-31 Sanofi Synthelabo Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
CA2564986A1 (en) 2004-05-10 2005-11-17 F. Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
WO2006067443A1 (en) 2004-12-23 2006-06-29 Astrazeneca Ab Therapeutic agents
EP1928859A1 (en) 2005-06-17 2008-06-11 Carex SA Pyrazole derivates as cannabinoid receptor modulators
WO2007046550A1 (en) 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
GB0622569D0 (en) 2006-11-11 2006-12-20 7Tm Pharma As Cannabinoid receptor modulators
WO2013003926A1 (pt) 2011-07-01 2013-01-10 Instituto De Pesquisas Tecnológicas Do Estado De São Paulo Processo de recuperação de liga lantanídeo-metal-metalóide em pó nanoparticulado com recuperação magnética e produto

Similar Documents

Publication Publication Date Title
JP2009529540A5 (enExample)
JP2009536221A5 (enExample)
JP2010511721A5 (enExample)
JP2007534702A5 (enExample)
JP2009535358A5 (enExample)
JP2008510828A5 (enExample)
JP2005523922A5 (enExample)
JP2011037841A5 (enExample)
JP2013537203A5 (enExample)
JP2015522650A5 (enExample)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
JP2011137006A5 (enExample)
JP2009504764A5 (enExample)
JP2014511891A5 (enExample)
JP2014528466A5 (enExample)
JP2013507423A5 (enExample)
JP2010536766A5 (enExample)
JP2007508362A5 (enExample)
JP2007510619A5 (enExample)
JP2007519721A5 (enExample)
JP2018135343A5 (enExample)
JP2010501478A5 (enExample)
JP2011227454A5 (enExample)
JP2005536519A5 (enExample)
JP2007519618A5 (enExample)